BRTX BioRestorative Therapies, Inc.

CIK 0001505497 50 ready 8-Ks latest October 9, 2026, 4:05 PM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline Risk accumulating: repeated leadership change (12)

Ready 8-Ks 50

Latest filing October 9, 2026, 4:05 PM ET

Top materiality 0.85

Event mix other_material ×32 · leadership ×6 · other ×5

Sentiment 5 pos · 8 neg · 37 neu

Latest earnings reported 2025-Q3

Executive change recent →

SHENANIGAN SCORE 3 / 7 see the board

Recent 8-K filings for BRTX

Highest-materiality recent filing

BioRestorative CEO and CFO resign; board appoints new CEO, investigates employment agreements

July 16, 2026, 5:30 PM ET leadership materiality 0.85 negative item 5.02 item 9.01

CEO Lance Alstodt and CFO Robert Kristal resigned July 13, 2026, claiming 'Good Reason' under alleged Change in Control; seek ~$2.85M aggregate severance plus equity acceleration.
Board appointed director Katharyn Field as CEO, President, and interim CFO; she also serves as CEO of iSpecimen (ISPC).

Read filing →

October 9, 2026, 4:05 PM ET leadership materiality 0.25 neutral item 5.02 item 9.01 ◈ executive_change ×2

BioRestorative Therapies appoints Donald J. Currie as Class I director, filling Katharyn Field vacancy

Currie, 65, appointed effective Oct 7, 2026, to serve until the 2027 annual meeting; fills the vacancy from Katharyn Field's resignation effective Aug 31, 2026.
September 11, 2026, 9:29 AM ET leadership materiality 0.50 negative item 5.02 item 9.01 ◈ executive_change

BioRestorative VP of R&D resigns claiming Good Reason; company disputes severance demand

Mr. Silva resigned as VP of R&D effective Sept 4, 2026, asserting 'Good Reason' under employment agreement due to alleged Change in Control from June 2026 board changes.
September 10, 2026, 4:30 PM ET other material materiality 0.80 negative item 4.01 item 8.01 item 9.01

BioRestorative dismisses CBIZ, hires Bush CPA; audit committee probe ongoing

Dismissed CBIZ as auditor effective Aug 28, 2026; board approved Aug 26, audit committee ratified Sep 1.
September 2, 2026, 5:29 PM ET other material materiality 0.75 neutral item 3.03 item 5.03 item 7.01 item 9.01

BioRestorative Therapies announces 1-for-20 reverse stock split to regain Nasdaq compliance

1-for-20 reverse split effective 4:30 p.m. ET Sept 7, 2026; trading starts Sept 8, 2026 on Nasdaq under BRTX with new CUSIP 090655705.
September 1, 2026, 6:09 PM ET leadership materiality 0.75 negative item 4.01 item 5.02 item 9.01 ◈ executive_change ×5

BioRestorative appoints Mika Grasso interim CEO, Anna Skowron CFO; dismisses auditor CBIZ

Katharyn Field steps down as interim CEO/CFO, resigns from board; consulting deal with EEAK at $10k/month.
August 25, 2026, 5:00 PM ET regulatory materiality 0.75 negative item 3.01 item 9.01

BioRestorative Therapies receives Nasdaq delisting notice for late 10-Q filing

Received Nasdaq delinquency notice on Aug 21, 2026 for failure to file Form 10-Q for Q2 2026.
August 14, 2026, 4:15 PM ET regulatory materiality 0.75 negative item 8.01 item 9.01

BioRestorative suspends ExoCR and BioX product shipments pending regulatory review

Suspended all orders and shipments of ExoCR and BioX biocosmeceutical product lines effective August 7, 2026.
July 16, 2026, 5:30 PM ET leadership materiality 0.85 negative item 5.02 item 9.01

BioRestorative CEO and CFO resign; board appoints new CEO, investigates employment agreements

CEO Lance Alstodt and CFO Robert Kristal resigned July 13, 2026, claiming 'Good Reason' under alleged Change in Control; seek ~$2.85M aggregate severance plus equity acceleration.
June 12, 2026, 5:00 PM ET other material materiality 0.20 neutral item 5.02 item 9.01

BioRestorative Therapies extends VP R&D Silva's employment; $575K salary unchanged, term to June 2029

New employment agreement for VP R&D Francisco Silva, effective June 10, 2026, with term through June 10, 2029.
June 12, 2026, 4:56 PM ET leadership materiality 0.75 neutral item 1.01 item 5.02 item 9.01 ◈ executive_change ×6◈ Material Agreements

BioRestorative Therapies enters $1M revolving loan at 12% with Bowery Group; board overhaul with 3 new directors

Entered $1,000,000 revolving loan agreement with Bowery Group LLC at 12% interest, 16% default rate, 1-year maturity.
May 29, 2026, 5:07 PM ET other material materiality 0.70 neutral item 5.02 item 5.07 item 9.01 ◈ Shareholder Votes

BRTX shareholders approve 20x increase in authorized shares; CEO/CFO sign 3-year employment agreements

CEO Lance Alstodt signed 3-year employment agreement with $600k annual salary, unchanged.
May 1, 2026, 7:59 PM ET other material materiality 0.50 neutral item 5.02

BioRestorative Therapies approves 2025 executive bonuses; CEO bonus $300K, VP $287.5K, CFO $140K

CEO Lance Alstodt awarded $300K cash bonus and $1.5M in option awards; total 2025 compensation $2.4M.
April 23, 2026, 7:59 PM ET other material materiality 0.20 neutral item 7.01 item 9.01

BioRestorative Therapies posts updated corporate presentation; no financial details disclosed

Updated presentation made available on company website on April 23, 2026.
February 17, 2026, 6:59 PM ET other material materiality 0.55 neutral item 1.01 item 7.01 item 9.01 ◈ Material Agreements

BioRestorative raises $5.0M in public offering of stock and warrants to fund clinical programs

Offering of 14.3M shares (or pre-funded warrants) and 14.3M five-year warrants at $0.35/unit closed Feb 13.
November 12, 2025, 6:59 PM ET earnings materiality 0.50 neutral item 2.02 item 7.01 item 9.01

BioRestorative Therapies reports Q3 2025 results; press release content omitted from filing

Press release dated November 12, 2025, announced Q3 2025 financial results and business update.
October 8, 2025, 7:59 PM ET other material materiality 0.45 neutral item 1.01 item 3.02 item 7.01 item 9.01 ◈ Equity Issuances

BioRestorative Therapies raises $1.085M in registered direct offering at $1.60/share; warrants at $2.75

Registered direct offering of 678,125 shares at $1.60/share, gross proceeds $1.085M; closing expected Oct 8, 2025.
September 25, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07

BioRestorative Therapies shareholders elect directors, approve stock plan amendment, ratify auditor, okay exec pay

Elected Francisco Silva (1.59M for) and David Rosa (1.47M for) as Class II directors; ~3.33M broker non-votes.
August 14, 2025, 7:59 PM ET other materiality 0.20 neutral item 7.01 item 9.01

BioRestorative Therapies releases updated corporate presentation; no financial details in filing

Updated investor presentation posted on company website and furnished as Exhibit 99.1.
August 12, 2025, 7:59 PM ET earnings materiality 0.50 neutral item 2.02 item 7.01 item 9.01

BioRestorative Therapies issues Q2 2025 earnings; no figures in provided excerpt

Press release dated Aug 12, 2025 announces Q2 financial results and a business update.
June 13, 2025, 7:59 PM ET other material materiality 0.78 positive item 7.01 item 9.01

BioRestorative presents Phase 2 data for BRTX-100: >50% improvement in pain/function in >70% of subjects

Preliminary blinded data from 36 subjects in Phase 2 trial of BRTX-100 for chronic lumbar disc disease presented at ISSCR 2025.
May 14, 2025, 7:59 PM ET earnings materiality 0.30 neutral item 2.02 item 7.01 item 9.01

BioRestorative Therapies issues Q1 2025 results press release; financial details not available

Company announced Q1 2025 financial results and business update on May 14, 2025.
April 21, 2025, 7:59 PM ET other material materiality 0.60 neutral item 4.01 item 9.01 ◈ Auditor Changes ×2

BioRestorative Therapies replaces auditor Marcum with CBIZ after Marcum attest business acquired

Marcum LLP resigned as auditor on April 16, 2025; FY2024 and FY2023 reports unqualified except FY2024 includes going-concern paragraph.
March 27, 2025, 7:59 PM ET other materiality 0.30 neutral item 2.02 item 7.01 item 9.01

BioRestorative Therapies to release FY2024 results after market close on March 27, 2025, with conference call

Financial results for year ended Dec 31, 2024 will be released after market close on March 27, 2025.
February 10, 2025, 6:59 PM ET other material materiality 0.20 neutral item 7.01 item 9.01

BioRestorative Therapies presents at ORS 2025; VP Silva discusses development programs

Francisco Silva, VP of R&D, presented at Orthopaedic Research Society 2025 Annual Meeting on Feb 8.
November 13, 2024, 6:59 PM ET other material materiality 0.75 positive item 2.02 item 7.01 item 9.01

BioRestorative Q3 operating loss narrows 26% YoY; BRTX-100 Phase 2 data shows improvement

Q3 2024 operating loss $2.3M vs $3.1M YoY (26% improvement); net loss $1.1M ($0.13/sh).
November 7, 2024, 6:59 PM ET other material materiality 0.55 neutral item 7.01 item 9.01

BioRestorative to present Phase 2 BRTX-100 data at spine symposium; Q3 results call Nov 13

Additional preliminary 26-52 week blinded data from Phase 2 trial of BRTX-100 for chronic lumbar disc disease to be presented on Nov 13, 2024.
November 6, 2024, 6:59 PM ET other material materiality 0.50 neutral item 1.01 item 1.02 item 9.01

BioRestorative enters into $3.6M ATM offering agreement with Rodman & Renshaw; terminates prior JonesTrading ATM

Entered ATM agreement with Rodman & Renshaw on Nov 6, 2024 for up to $3.6M of common stock.
September 23, 2024, 7:59 PM ET other material materiality 0.15 neutral item 5.07

BioRestorative shareholders approve doubling of stock incentive plan shares to 6.85M

Class I director Nickolay Kukekov re-elected with 2,050,111 votes for, 135,114 withheld, 2,048,738 broker non-votes.
August 13, 2024, 7:59 PM ET earnings materiality 0.50 neutral item 2.02 item 7.01 item 9.01

BioRestorative Therapies issues Q2 2024 results press release; specific figures not provided

Press release announcing Q2 2024 financial results was issued on August 13, 2024.
August 6, 2024, 7:59 PM ET other materiality 0.15 neutral item 2.02 item 7.01 item 9.01

BioRestorative Therapies schedules Q2 2024 earnings release and call for Aug 13

Financial results for Q2 2024 will be released after market close on Tuesday, August 13, 2024.
May 24, 2024, 7:59 PM ET other material materiality 0.70 negative item 4.02

BioRestorative Therapies restates financials due to warrant classification error; no cash impact

Previously issued annual (FY2023) and quarterly (Q1'22–Q3'23) financial statements should no longer be relied upon.
May 24, 2024, 7:59 PM ET regulatory materiality 0.70 negative item 3.01

BioRestorative receives Nasdaq notice for late 10-Q filing; no immediate delisting

Nasdaq notified BioRestorative on May 22, 2024 of non-compliance with Listing Rule 5250(c)(1) due to delinquent Form 10-Q for Q1 2024.
March 12, 2024, 7:59 PM ET other materiality 0.15 neutral item 7.01 item 9.01

BioRestorative Therapies to present at 36th Annual ROTH Conference on March 18, 2024

CEO Lance Alstodt to participate in fireside chat on March 18, 2024 at 12:00pm PDT.
February 8, 2024, 6:59 PM ET other material materiality 0.70 neutral item 1.01 item 3.02 item 8.01 item 9.01 ◈ Material Agreements

BioRestorative raises $8.1M via warrant exercise and new private placement warrants

Gross proceeds of $8.1M from exercise of existing warrants for 3,351,580 shares at $2.33/share.
February 5, 2024, 6:59 PM ET other material materiality 0.75 positive item 7.01 item 9.01

BioRestorative reports positive preliminary Phase 2 data for BRTX-100 in chronic lumbar disc disease

Preliminary 26-52 week blinded data from Phase 2 trial of BRTX-100 presented at ORS 2024 Annual Meeting.
February 1, 2024, 6:59 PM ET other material materiality 0.50 neutral item 7.01 item 9.01

BioRestorative to present Phase 2 BRTX-100 data at ORS meeting, host webcast Feb 5

Preliminary 26-52 week blinded data from Phase 2 trial of BRTX-100 for chronic lumbar disc disease to be presented at ORS 2024 Annual Meeting Feb 2-6 in Long Beach.
September 15, 2023, 7:59 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×3

BRTX stockholders elect directors, approve share increase, ratify auditor at annual meeting

Class III directors Lance Alstodt and Patrick F. Williams elected with 864,671 and 662,099 votes for, respectively.
July 13, 2023, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 8.01 item 9.01 ◈ Material Agreements ×2

BRTX prices $2.1M registered direct offering of 685,033 shares at $3.03/share

Offering of 685,033 shares at $3.03/share for gross proceeds of approximately $2.1M; closing expected July 13, 2023.
April 14, 2023, 7:59 PM ET other material materiality 0.50 neutral item 1.01 item 9.01 ◈ Material Agreements

BioRestorative enters ATM equity facility with JonesTrading for up to $3.7M

Capital On Demand Sales Agreement signed April 14, 2023 with JonesTrading Institutional Services LLC.
April 6, 2023, 7:59 PM ET other materiality 0.00 neutral item 8.01 item 9.01

BioRestorative Therapies files accounting firm consents for S-3 registration statement

Filed consents of Friedman LLP and Marcum LLP to incorporate audit reports into Form S-3.
January 5, 2023, 6:59 PM ET other material materiality 0.35 neutral item 3.03 item 9.01

BioRestorative Therapies reincorporates from Delaware to Nevada as of Dec 31, 2022

Reincorporation approved by stockholders on Nov 3, 2022; effective Dec 31, 2022 via merger of DE corp into NV subsidiary.
November 9, 2022, 6:59 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×6

BioRestorative shareholders approve all proposals, including reincorporation to Nevada

Elected David Rosa and Francisco Silva as Class II directors; 1.8M and 1.95M shares for, respectively.
September 13, 2022, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 4.01 item 5.03 item 7.01 item 9.01

BioRestorative exchanges preferred shares with Auctus, replaces auditor after Friedman/Marcum merger

Issued 1,543,158 Series B preferred shares to Auctus Fund in exchange for same number of Series A shares on Sept 8, 2022.
December 8, 2021, 6:59 PM ET leadership materiality 0.35 neutral item 5.02 item 9.01

BioRestorative Therapies enters CFO employment agreement with $175K salary, stock option grant

CFO Robert E. Kristal employment agreement effective Nov 4, 2021, term through Nov 4, 2022.
November 19, 2021, 6:59 PM ET other material materiality 0.30 neutral item 5.03 item 9.01

BioRestorative reduces authorized shares to 75M after 1-for-4,000 reverse split

Board approved reduction of authorized common shares from 300B to 75M, consistent with the 1-for-4,000 reverse split ratio.
November 15, 2021, 6:59 PM ET other material materiality 0.60 positive item 3.02 item 7.01 item 9.01

BioRestorative closes $23M public offering, swaps $10M notes for equity

Closed underwritten public offering of 2.3M units at $10 each, gross proceeds ~$23M. Each unit: 1 common share + 1 warrant.
November 8, 2021, 6:59 PM ET other material materiality 0.75 positive item 1.01 item 5.02 item 7.01 item 9.01 ◈ executive_change ×3

BioRestorative Therapies prices $23M public offering, uplists to Nasdaq; appoints CFO and new directors

Priced underwritten public offering of 2.3M units at $10/unit for gross proceeds of $23M; net proceeds ~$20.87M.
October 26, 2021, 7:59 PM ET other material materiality 0.50 neutral item 5.03 item 8.01 item 9.01

BioRestorative Therapies announces 1-for-4,000 reverse stock split effective Oct 27

Board approved and stockholders authorized a 1-for-4,000 reverse split of common stock.
October 20, 2021, 7:59 PM ET other material materiality 0.80 neutral item 1.01 item 9.01

BioRestorative Therapies enters agreements to exchange $9.25M notes and warrants for units in proposed offering

Exchanged aggregate $9,246,897 principal of convertible notes and warrants for units in proposed public offering.
August 17, 2021, 7:59 PM ET other material materiality 0.55 neutral item 5.07

BioRestorative Therapies shareholders approve reverse stock split, reject Nevada reincorporation

Elected Nickolay Kukekov as Class I director: 1.49B for, 132.6M withheld, 452M broker non-votes.